ENVB · Enveric Biosciences, Inc.
$1.33
+0.00 (+0.00%)
At close · Jul 29
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed May 15, 2026
Market Cap
$4.90M
Shares
3.68M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Joseph Tucker | CEO | $879,541 |
| Kevin Coveney | CFO | $678,445 |
| Peter Facchini | Chief Innovation Officer | $253,172 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Joseph Tucker | CEO | $611,533 |
| Kevin Coveney | CFO | $478,002 |
| Peter Facchini | Chief Innovation Officer | $274,580 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Joseph Tucker | CEO | $577,094 |
| Kevin Coveney | CFO | $358,677 |
| Peter Facchini | Chief Innovation Officer | $282,091 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Avani Kanubaddi | COO | $1,300,597 |
| Joseph Tucker | CEO | $825,937 |
| Peter Facchini | Chief Innovation Officer | $332,375 |
| Kevin Coveney | CFO | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Avani Kanubaddi | COO | $4,236,593 |
| Peter Facchini | Chief Innovation Officer | $1,704,608 |